Welcome to our dedicated page for Marpai news (Ticker: MRAI), a resource for investors and traders seeking the latest updates and insights on Marpai stock.
Marpai, Inc. reports recurring developments in healthcare technology, third-party administration and pharmacy benefit management services for employers that directly fund employee health benefits. The company operates subsidiaries that provide TPA, PBM and value-oriented health plan services, including the MarpaiRx pharmacy benefit platform and the Marpai Saves initiative.
News about MRAI commonly covers MarpaiRx client wins, marketing collaborations, network access arrangements with providers such as Aetna and Cigna, financial results, operating efficiency initiatives and leadership changes tied to its health benefits administration business.
Marpai, Inc. (NASDAQ: MRAI) has appointed Gonen Antebi as its new Chief Operating Officer, bringing significant experience from his tenure as CEO at Nuvem Health. Mr. Antebi has previously led operations at ArroHealth and MedSave USA, enhancing healthcare delivery and profitability. He replaces Ronnie Brown, who will continue to serve as an advisor. Antebi's leadership is expected to drive Marpai's growth in the TPA sector, particularly following the recent acquisition of Maestro Health. Marpai aims to leverage AI technology to optimize self-funded employer health plans and enhance cost efficiency.
Summary not available.
Marpai (Nasdaq: MRAI) announced the addition of Virta Health as a Premium Health Partner to enhance diabetes management for its health plan members. This partnership aims to provide effective solutions for reversing type 2 diabetes, addressing the growing issue that affects nearly 133 million Americans. Virta's approach focuses on sustainable health improvements without the typical risks associated with medications. Marpai's Proactive Targeted Health Interventions will make Virta's services available to all members upon renewal or new enrollment beginning January 1, 2023.
Marpai, Inc. (Nasdaq: MRAI) reported Q3 2022 financial results, with net revenue of approximately $4.9 million, down 11.1% from Q2 2022. This decline was attributed to a reduction in employees covered under their plans, which dropped to 16,357 by September 30, 2022. Operating expenses decreased to around $10.8 million, yet the net loss was approximately $5.8 million. Following the acquisition of Maestro Health, Marpai aims to integrate operations and expand its customer base significantly. Financial guidance for Q4 2022 remains undisclosed due to the acquisition.
Marpai, Inc. (Nasdaq: MRAI) will hold a conference call on November 10, 2022, at 8:30 a.m. ET to discuss its Q3 2022 financial results. The results will be released after market close on November 9, 2022. Marpai operates in the $22 billion Third Party Administrator sector, focusing on self-funded health plans. With AI-driven services, the company aims to enhance health outcomes and value-based care while managing substantial annual claims exceeding $1 trillion.
Marpai, Inc. (Nasdaq: MRAI) has launched MarpaiRx, an innovative pharmacy benefit management (PBM) solution aimed at lowering drug costs for self-insured health plans. Collaborating with MedOne Pharmacy Benefit Solutions, MarpaiRx focuses on enhancing member experiences and reducing costs through a patient-centric approach. It offers a formulary based on drug outcome performance and ensures transparency by passing all discounts directly to clients. Leveraging AI technology, MarpaiRx aims to simplify access to affordable medications while addressing the growing expenses associated with pharmacy benefits.
Marpai, Inc. (MRAI) reported Q2 2022 results, with net revenue of approximately $5.6 million, down 10.6% from Q1's $6.2 million. The decline was attributed to a drop in employees covered under its health plans, decreasing to 21,074 from 25,195 a year prior. Operating expenses rose to $12.2 million, while net loss widened to $6.7 million compared to $5.5 million in the previous quarter. The company is focused on its January 1, 2023 sales period and the upcoming acquisition of Maestro Health, which may impact future results.
Marpai, Inc. (Nasdaq: MRAI) announced its definitive agreement to acquire Maestro Health, a leading Third-Party Administrator (TPA) based in Chicago, for $22.1 million. This acquisition, expected to close within 60 days, will combine resources, doubling Marpai's revenues and expanding its customer base to over 40,000 employee lives with projected combined revenues of $40 million in 2022. The merger includes over $20 million in cash expected at closing to finance integration and aims for positive EBITDA within 18 months.
Marpai, Inc. (Nasdaq: MRAI) will host a conference call on August 11, 2022, at 8:30 a.m. ET to discuss its Q2 2022 financial results. The results will be reported after market close on August 10, 2022. Marpai focuses on transforming the third-party administration (TPA) sector in the self-funded health insurance market, utilizing AI-driven solutions to enhance health plan effectiveness. Serving a market valued at $22 billion, the company aims to improve health outcomes through a member-centric approach, leveraging data to ensure cost-effective healthcare delivery.
Marpai (Nasdaq: MRAI) hosted its second annual Broker Retreat in Ft. Lauderdale, showcasing Dr. Marty Makary as the keynote speaker. The event focused on utilizing big data and AI to enhance healthcare outcomes in self-insured plans. Dr. Makary emphasized the importance of quality metrics in transforming healthcare systems and reducing unnecessary medicalization. Marpai's member-centric approach aims to connect members with effective health solutions and promote value-based care. Key insights from the event highlight Marpai's commitment to improving health while managing costs in the $22B Third-Party Administrator market.